Matches in Wikidata for { <http://www.wikidata.org/entity/Q94145086> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- Q94145086 description "article published in 2019" @default.
- Q94145086 description "article scientifique publié en 2019" @default.
- Q94145086 description "artículu científicu" @default.
- Q94145086 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q94145086 description "wetenschappelijk artikel" @default.
- Q94145086 description "наукова стаття, опублікована у 2019" @default.
- Q94145086 name "661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)" @default.
- Q94145086 name "661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)" @default.
- Q94145086 type Item @default.
- Q94145086 label "661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)" @default.
- Q94145086 label "661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)" @default.
- Q94145086 prefLabel "661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)" @default.
- Q94145086 prefLabel "661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)" @default.
- Q94145086 P1433 Q94145086-3699FBDE-C6DE-4B89-A4A8-CDB30F93EE4F @default.
- Q94145086 P1476 Q94145086-B3A4447D-AB19-47EA-A8E4-95AB13A8D9F9 @default.
- Q94145086 P2093 Q94145086-0C3C4349-5624-4AAF-BA67-C30B3C5C7C9C @default.
- Q94145086 P2093 Q94145086-34490352-4DFC-4241-A253-159054CBC1F3 @default.
- Q94145086 P2093 Q94145086-655B2BD8-470D-43B9-8C0C-C0093E2A1146 @default.
- Q94145086 P2093 Q94145086-70A06ADE-2F04-49FB-8F77-B38901F9BB87 @default.
- Q94145086 P2093 Q94145086-B2E3E15B-C02F-4E6F-B9B5-4E1C693D5C28 @default.
- Q94145086 P2093 Q94145086-C53A12CF-EF09-493A-81F9-07125A063296 @default.
- Q94145086 P2093 Q94145086-F81FB89C-8C3A-4DE4-8347-C0EC8FC06D12 @default.
- Q94145086 P275 Q94145086-7a505152-e65e-4a40-978c-3fd997af6874 @default.
- Q94145086 P304 Q94145086-C8CFCF93-D5FD-4704-892B-8F292227ED29 @default.
- Q94145086 P31 Q94145086-1C522F02-0550-44E3-B0AE-9CC47D7C0545 @default.
- Q94145086 P356 Q94145086-B8AB8AD2-5D4E-47FD-9A13-655ACE9B96F3 @default.
- Q94145086 P433 Q94145086-2CCDF3E1-00A1-4738-A890-E839402D3055 @default.
- Q94145086 P478 Q94145086-9CFF3064-257D-4B0B-8AC2-983259D7E44B @default.
- Q94145086 P577 Q94145086-353F1964-A680-4862-BA63-381C977EB8BA @default.
- Q94145086 P6216 Q94145086-4d5ac8a8-329e-4dc6-8322-239b3bbfc9ca @default.
- Q94145086 P921 Q94145086-D1B822E8-FA61-4368-B0ED-1665343F7192 @default.
- Q94145086 P932 Q94145086-E21ED2B2-8544-4F9C-B4FF-31DDA939A031 @default.
- Q94145086 P356 OFZ360.729 @default.
- Q94145086 P1433 Q27725953 @default.
- Q94145086 P1476 "661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)" @default.
- Q94145086 P2093 "Brinda Emu" @default.
- Q94145086 P2093 "Catherine Creticos" @default.
- Q94145086 P2093 "Edwin DeJesus" @default.
- Q94145086 P2093 "Jason Leider" @default.
- Q94145086 P2093 "Mezgebe Berhe" @default.
- Q94145086 P2093 "Steve Weinheimer" @default.
- Q94145086 P2093 "Zvi Cohen" @default.
- Q94145086 P275 Q24082749 @default.
- Q94145086 P304 "S303-S303" @default.
- Q94145086 P31 Q13442814 @default.
- Q94145086 P356 "10.1093/OFID/OFZ360.729" @default.
- Q94145086 P433 "Suppl 2" @default.
- Q94145086 P478 "6" @default.
- Q94145086 P577 "2019-10-23T00:00:00Z" @default.
- Q94145086 P6216 Q50423863 @default.
- Q94145086 P921 Q407954 @default.
- Q94145086 P932 "6811265" @default.